Maxcyte Share Discussion Threads

[danieldruff2] 06/1/2021 10:02

Can this be bought as a UK share still? I tried to buy with EQi but they would only list the Nasdaq version.

[someuwin] 06/1/2021 09:14

Stock very tight again. Could see a big move up soon.

[assagai] 05/1/2021 20:08

Err , still on the move, surely?
I think of it as the maximum trampoline depression prior to the fat man being catapulted towards the heavens.
PS a kindly "net man" then hauls him onto the platform.

...he does not fall back to earth.
Wrong this time Isaac....

[saucepan] 05/1/2021 14:52

On the move.

[someuwin] 31/12/2020 09:42

Not long to wait until next news...

"Based on ongoing momentum in transformational cell therapies and milestone payments from growth in clinical and commercial license partnerships, MaxCyte expects financial results to be ahead of market expectations for the full-year in the core life sciences business (before CARMA costs). A more detailed trading update will be announced the week of 18 January 2021.

MaxCyte continues to work with Locust Walk on the strategy and future funding of the Group's CARMA business, and enrolment and dosing in the existing CARMA no-preconditioning MCY-M11 clinical study is continuing well. The Company will provide a further update in January."

[assagai] 30/12/2020 10:16

Hi Bamboo, yes that's correct under the aim rules. Not sure what the percentage is without tedious research but I think it's around 15 to 20% above market expectations of earlier projected figures . Of course it can mean a larger margin but the 15/20 is justthe trigger.
If I have time today I'll trawl through the AIM rules.

Edit i stand corrected , this does not apply to AIM.

I have had a conversation with the AIM dept at LSE and there is no specific requirement to trigger this with AIM companies. The most likely explanation I was given is that whilst the company is generally aware of its "outperform" status it likely requires confirmation from its Auditors before fleshing it out - hence the gap.

[bamboo2] 30/12/2020 09:55

Hi Assagai, I don't think they had a choice about the timing of the recent rns. They are obliged to make an announcement if there is a change to the outlook.
Maybe someone else knows for certain if this is true?

Welcome Saucepan.

[saucepan] 30/12/2020 08:48

Recently long here. I agree it looks a good one for 2021.

[someuwin] 30/12/2020 08:24

No buy quote available.

[nimbo1] 29/12/2020 21:13

Adam give it 2-5 years, it might qualify for your large cap portfolio : )

[assagai] 29/12/2020 19:46

Someuwin, hopefully 100% next year is conservative but let's finish this one first! It struck me as strange that they would bother to issue trading update on the 23rd only to announce a more detailed update within a month. Well let's see but it may be that as they had suggested earlier in the year that Carma would be independent in 2020 ,as that date is unlikely, maybe the Jan update might just be to include that?? Just guessing but it would also be good to get an update on Nas listing. It was also unusual to mention earlier that their Accountants received payments for non audit related work.. a hint on timetable?

Anyway , really happy with the way this is apparently heading and STILL largely under the radar

Adam, it's my largest holding, full stop.....by a mile.

[adamb1978] 29/12/2020 19:29

Nice increase today. This is my largest position in my small/mid cap portfolio

[nimbo1] 29/12/2020 19:05

interesting article about crispr, one of maxcyte's partners

[someuwin] 29/12/2020 08:54

Bought a few more here. Hoping for 100% or more in 2021.

[nimbo1] 24/12/2020 09:28

maxcyte tweeted yesterday congratulating allogene (who they have a commercial agreement with) for this milestone.

[someuwin] 24/12/2020 09:06

Still very strong here. Can't buy many at all.

[nimbo1] 23/12/2020 19:09

Many thanks for that very informative post. The only other business I know with the royalty potential as you describe is clearpoint neuro (CLPT) listed in the US. Its a really interesting business with 30 partners using their platform to investigate gene therapies for the brain. I've been invested since about $10. CLPT corse business is used in real procedures in US clinics and generates about $15 mil of income per annum.

Out of interest the 'royalty' for them isnt a set drug % fee but will be a fee on the consumables used in the brain procedures that use their patented equipment.

[gsbmba99] 23/12/2020 18:57

There are two businesses in one here which is exceptionally important from a valuation perspective - a fully owned clinical pipeline of unknown depth and a life sciences tools business that is so integral to the non-viral gene therapy process that it attracts exceptional gross margins, ~$15m in pre-commercial milestone payments per product and a very small royalty share. If anyone knows of other life sciences tools businesses that attract royalty shares, I would be very keen to know about them because I think they are exceedingly rare. The CARMA business has to date had a value of £100-150m attributed to it in analyst reports. CARMA has one target/indication with two forms of delivery and has been in the clinic for about 15 months. MXCT has not disclosed any part of the pre-clinical pipeline so it's very hard to value CARMA on the basis of the numbers of products it has at various stages of development by comparing it to other listed companies. However, there is reason to believe that a positive outcome for MCY-M11 could lead to multiple IND ready targets being added to the CARMA pipeline in short order. It has been hinted that there is no shortage of potential targets for CARMA. It is worth checking to see how a US gene therapy company with 1 intermediate clinical and 2-4 (or more) clinic ready products might be valued. I can think of one company that, until very recently, had no clinical products and two products 1-3 years away from the clinic with an EV >$1.7bn. Obviously, there are a whole host of caveats and we don't know if MCY-M11 has value applicable to other products or not and CARMA is not subject to the same relentless scrutiny by a community of exceptionally well informed US analysts. There is, however, a not unrealistic prospect that a CARMA valuation of £100-150m is too low by rather a lot. Hopefully there will be some third party validation attaching to the CARMA independent funding transaction and more on the pipeline. Who knows, we might even be getting the royalty attracting, recurring revenue, mission critical, high margin life sciences tools business for free!

[trident5] 23/12/2020 18:49

Well bad workmen always blame the tools.

[nimbo1] 23/12/2020 18:14

Trident5 filtered - you are a tool.

[trident5] 23/12/2020 17:50

AO sell fridges too - apply their market cap/revenue rating and Biolife would be valued at about 45mil.

[nimbo1] 23/12/2020 17:39

Biolife solutions valued at 1.5 bil on Nasdaq for 30 mil revenue. They make fridges for gene players like crispr among other things. Maxcyte is a much better proposition to play the space (given the geared upside to successful drugs) and this provides some sort of comparable imo due to picks and shovels nature.

[trickydicky1] 23/12/2020 13:19

Is this the next TSMC? Am skulking here very quietly looking for 100 bags from 2Q20 entry.

Think carefully.

[bamboo2] 23/12/2020 12:33

trident, I know you are not keen on charting, so apols in advance!

This mornings gap up measures 460-462
This is a Breakaway gap, the same as that dated 7/10/2020

They are often caused by news/rns events and typically remain unfilled.
There are some good examples, unfilled, lower down the KWS and FEVR charts.

The minimum price target for this move is 536